The use of mesenchymal stem cells in optic nerve atrophy in patients with multiple sclerosis: A pilot study

Cover Page

Abstract

Introduction. Cellular therapy of multiple sclerosis is currently considered to be one of the most promising treatment alternatives for this severe pathology of the nervous system.

Materials and Methods. Two patients with relapsing-remitting multiple sclerosis (RRMS) complicated by partial optic nerve atrophy (ONA) caused by bilateral retrobulbar optic neuritis received treatment using autologous multipotent mesenchymal stem cells (MSCs). MSCs were derived by bone marrow aspiration/biopsy followed by isolation, culturing, and cryostorage. MSCs were administered in compliance with the developed protocol by short-term intravenous infusion of resuspension solution of 5% glucose supplemented with 10% autoserum at a dose of 2.0×106/kg body weight in combination with local parabulbar administration of MSCs at a dose of 10×106 once per month during 4 months. The control group consisted of 2 patients of the same age with RRMS with partial ONA of the same severity who received background (metabolic and glucocorticoid) therapy.

Results. Neurological and neuro-ophthalmological examination was carried out before and 6 months after treatment. The pilot study performed demonstrated that the elaborated protocol for MSC therapy is safe and, according to the preliminary data, therapy was characterized by moderate clinical effectiveness in incurable patients with RRMS and ONA.

Conclusions. The findings make it possible to broaden the range of clinical studies focused on cellular therapy for multiple sclerosis.

About the authors

Gennadiy N. Bisaga

S. M. Kirov Military Medical Academy, St. Petersburg, Russia

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

Anzhelika V. Kovalenko

S. M. Kirov Military Medical Academy, St. Petersburg, Russia

Email: platonova@neurology.ru
Russian Federation

Galina E. Isaeva

S. M. Kirov Military Medical Academy, St. Petersburg, Russia

Email: platonova@neurology.ru
Russian Federation

Igor' Yu. Kovalenko

S. M. Kirov Military Medical Academy, St. Petersburg, Russia

Email: platonova@neurology.ru
Russian Federation

Andrey V. Novitsky

Clinical Hospital no. 122, Federal Medical-Biological Agency of the Russian Federation, St. Petersburg

Email: platonova@neurology.ru
Russian Federation

Igor' V. Litvinenko

S. M. Kirov Military Medical Academy, St. Petersburg, Russia

Email: platonova@neurology.ru
Russian Federation

References

  1. Bisaga G.N., Gaykova O.N., Onishchenko L.S. et al. Rasseyannyy skleroz: ot morfologii k patogenezu. [Multiple sclerosis: from morphology to pathogene-sis]. Saint-Petersburg. 2015. 104 p. (In Russ.)
  2. Shmidt T.E., Yakhno N.N. Rasseyannyy skleroz. [Multiple sclerosis]. Moscow: MEDpress-inform, 2010. 269 p. (In Russ.)
  3. Kovalenko A.V., Bisaga G.N., Gaykova O.N. et al. [Pathomorphological changes in the optic nerve and chiasma in multiple sclerosis].Vestnik Rossiyskoy voenno-meditsinskoy akademii.2011; 3: 126-132. (In Russ.)
  4. Wilhelm H., Schabet M. The diagnosis and treatment of optic neuritis. Deutsches Ärzteblatt International. 2015; 112 (37): 616-625. doi: 10.3238/arztebl.2015.0616. Review. PMID: 26396053;
  5. Boyko A.N., Boyko O.V., Gusev E.I. [The choice of the optimal preparation for the pathogenetic treatment of multiple sclerosis: the current state of the problem (review)]. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2014; 114 (10): 77-91. (In Russ.)
  6. Odinak M.M., Bisaga G.N., Novitskiy A.V. et al.[Transplantation of mesenchymal stem cells in multiple sclerosis]. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2011; 111 (2): 72-76. PMID: 21919233. (In Russ.)
  7. Fridenshteyn A.Ya., Luriya E.A. Kletochnye osnovy krovetvornogo mikrookruzheniya. [Cellular bases of the hematopoietic microenvironment]. Moscow: Meditsina., 1980.- 215 p. (In Russ.)
  8. Llufriu S., Sepúlveda M., Blanco Y. et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014; 9 (12): e113936. PMID: 25436769 doi: 10.1371/journal.pone.0113936
  9. Polman C.H., Reingold S.C., Banwell B. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011; 69 (2): 292-302. PMID: 21387374 doi: 10.1002/ana.22366
  10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33 (11): 1444-1452. PMID: 6685237

Statistics

Views

Abstract: 1260

PDF (Russian): 789

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2017 Bisaga G.N., Kovalenko A.V., Isaeva G.E., Kovalenko I.Y., Novitsky A.V., Litvinenko I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies